{"id":"tqb3454-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By targeting this enzyme, TQB3454 aims to disrupt the metabolic pathways that support tumor growth and survival, potentially leading to reduced tumor size and slowed disease progression.","oneSentence":"TQB3454 is designed to inhibit the activity of a specific enzyme involved in the progression of certain cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:38.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT05987358","phase":"PHASE3","title":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-09-21","conditions":"Biliary Carcinoma","enrollment":165},{"nctId":"NCT06218771","phase":"PHASE1, PHASE2","title":"A Study of TQB3454 Tablets in Patients With Blood Tumors","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT06139367","phase":"PHASE1","title":"A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-11","conditions":"Biliary Carcinoma","enrollment":40},{"nctId":"NCT04481607","phase":"PHASE1","title":"A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-08-24","conditions":"Advanced Solid Tumor or Hematologic Tumor","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46976,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQB3454 Tablets","genericName":"TQB3454 Tablets","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQB3454 Tablets are a small molecule intervention being studied in clinical trials for various conditions, including Advanced Solid Tumor or Hematologic Tumor, Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Biliary Carcinoma. The mechanism of action of TQB3454 Tablets is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}